Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported in part by educational grants from Celgene Corporation, Genentech, Lilly USA, LLC, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, and Seattle Genetics, Inc.
Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

17th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

17th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma


Friday, February 15, 2013  
7:00 am Registration and Breakfast  
8:00 am Welcome Andrew Zelenetz, MD, PhD
T-Cell Lymphoma Moderator: Steven Horwitz, MD
8:05 am Introductions & Pre-session Outcomes Survey Steven Horwitz, MD
8:15 am Lymphoma Classification and the Impact of Genomics Randy Gascoyne, MD
8:35 am Initial Management of Peripheral T Cell Lymphoma: If CHOP is no good, what is? Steven Horwitz, MD
8:50 am Comment Ranjana Advani, MD
  Debate: Role of HDT/ASCR in initial management of PTCL Moderator: Steven Horwitz, MD
8:55 am Pro Lauren Pinter Brown, MD, FACP
9:10 am Con Pier Luigi Porcu, MD
9:25 am Management of CD30+ Lymphoma Ranjana Advani, MD
9:40 am Comment Steven Horwitz, MD
9:45 am Break  
10:10 am Management of CTCL Lauren Pinter Brown, MD, FACP
10:25 am Comment Pier Luigi Porcu, MD
10:30 am Audience Question and Answer All Faculty
10:40 am Case-Based Discussion All Faculty
11:00 am Post-Session Outcomes Survey  
Chronic Myeloid Leukemia and Myeloproliferative Disorder Moderator: Dr. Harry Erba
11:05 am Pre-session Outcomes Survey  
  Debate: First line treatment of CML: 2nd generation TKI or optimized Imatinib? Moderator: Harry Erba, MD, PhD
11:10 am Imatinib Harry Erba, MD, PhD
11:25 am 2nd Generation TKIs Michael Mauro, MD
11:40 am Can therapy with TKIs ever be stopped? Should this be the primary goal of treatment? Moishe Talpaz, MD
11:55 am Comment Michael Mauro, MD
12:00 pm How to monitor patients receiving TKIs for CML Harry Erba, MD, PhD
12:15 pm The management of accelerated and myeloid blast phase CML Richard Stone, MD
12:30 pm Adjourn for Lunch  
Chronic Myeloid Leukemia and Myeloproliferative Disorders (Continued)  
1:45 pm Interferon Therapy for MPDs Richard Silver, MD
2:00 pm All JAKed Up and No Place to Go - A Critical Evaluation of the Role of JAK2 Inhibitors Ruben Mesa, MD
2:15 pm Audience Question & Answer All Faculty
2:25 pm Case-Based Discussion All Faculty
2:45 pm Post-Session Outcomes Survey  
2:50 pm Break  
Multiple Myeloma Moderator:  Sundar Jagannath, MD
3:20 pm Pre-session Outcomes Survey  
3:25 pm What Can We Learn From Multiple Myeloma Genomic Analysis? Nikhil Munshi, MD
3:40 pm High Risk Smoldering Myeloma - Should We Intervene Early? Ola Landgren, PhD
3:55 pm Current Trends: Treatment Strategies for Newly Diagnosed Elderly Patients with Myeloma James Berenson, MD
  Debate: HDT/ASCR for MM: Upfront v Relapse Moderator: Sundar Jagannath, MD
4:10 pm Upfront James Berenson, MD
4:25 pm Relapse Nikhil Munshi, MD
4:40 pm Maintenance Therapy - Is It for Everyone? Nikhil Munshi, MD
4:55 pm How To Best Use New Proteasome Inhibitors and IMiDs in Myeloma Sundar Jagganath, MD
5:10 pm Audience Question & Answer All Faculty
5:20 pm Case-Based Discussion All Faculty
5:40 pm Post-Session Outcomes Survey  
5:45 pm Adjourn  
Saturday, February 16, 2013  
7:00 am Breakfast  
New Directions in Chronic Lymphocytic Leukemia Moderator: William Wierda, MD, PhD
8:00 am Welcome and Pre-session Outcomes Survey  
8:10 am Prognostic Factors: How To use in Clinical Practice William Wierda, MD, PhD
8:25 am Treatment for Elderly CLL: Is There A Standard? Alessandra Ferrajoli, MD
8:40 am Targeted Therapy for CLL: Focusing on the B Cell Receptor Pathway Jennifer Brown, MD, PhD
8:55 am Targeting BCL-2 to Treat CLL Tom Kipps, MD, PhD
9:10 am IMiDs and Combinations: How To Integrate into Standard Therapy Alessandra Ferrajoli, MD
9:25 am Audience Question & Answer All Faculty
9:35 am Cased-Based Discussion All Faculty
9:55 am Post-Session Outcomes Survey  
10:00 am Break  
Acute Myeloid Leukemia and Myelodysplastic Syndrome Moderator: William Wierda, MD, PhD
10:25 am Pre-session Outcomes Survey  
10:30 am Can ‘pediatric’-like strategies be safely applied to adults with acute lymphocytic leukemia?  Daniel DeAngelo, MD, PhD
  Debate: Should patients with high risk MDS (and AML in early relapse) proceed directly to allogeneic transplantation without prior induction chemotherapy? William Wierda, MD, PhD
10:45 am Yes Virginia Klemik, MD
11:00 am No Harry Erba, MD, PhD
  Debate: Should older patients with AML be considered for lower intensity approaches rather than 3 & 7? Moderator: William Wierda, MD, PhD
11:15 am Yes Richard Stone, MD
11:30 am No Eric Feldman, MD, PhD
11:45 am Is molecular characterization of cytogenetically normal AML helpful clinically? Ross Levine, MD
12:00 pm The management of patients with MDS refractory to hypomethylating agents David Steensma, MD
12:15 pm BiTES Daniel DeAngelo, MD, PhD
12:30 pm Audience Question & Answer All Faculty
12:40 pm Case-Based Discussion All Faculty
12:55 pm Post-Session Outcomes Survey  
1:00 pm Adjourn for Lunch  
B Cell Lymphoma  
2:15 pm Pre-session Outcomes Survey  
2:20 pm Keynote: Epigenetics of Lymphoma Ari Melnik, MD
2:50 pm How I Manage Early-Stage DLBCL Daniel Persky, MD
3:05 pm Comment Craig Moskowitz, MD
3:10 pm Advanced-Stage DLBCL Craig Moskowitz, MD
3:20 pm Comment Andre Goy, MD
3:25 pm Break  
3:55 pm Relapsed DLBCL in the Rituximab Era Anas Younes, MD
4:10 pm Comment Craig Moskowitz, MD
4:15 pm New Directions in Follicular Lymphoma Bruce Cheson, MD
4:30 pm Comment Andrew Zelenetz, MD, PhD
4:35 pm Stem Cell Transplantation in Indolent Lymphoma Andre Goy, MD
4:50 pm Comment Bruce Cheson, MD
4:55 pm Audience Question and Answer All Faculty
5:05 pm Post-Session Outcomes Survey  
5:10 pm Adjourn  
Sunday, February 17, 2013  
7:00 am Breakfast  
Supportive Care Moderator: Andrew Zelenetz, MD, PhD
8:00 am Pre-session Outcomes Survey  
8:05 am Management of Thrombocytopenia James Bussel, MD
8:20 am Hepatitis B and Hematologic Malignancies Andrew Zelenetz, MD, PhD
8:35 am Special Issues in Managing Hematologic Malignancies in the Adolescent and Young Adult Patrick Brown, MD
8:50 am Adaptive Trial Design Using Surrogate Outcomes Don Berry, PhD
9:05 am Audience Question and Answer  
9:15 am Post-Session Outcomes Survey  
Hodgkin Lymphoma Moderator: Andrew Zelenetz, MD, PhD
9:20 am Pre-session Outcomes Survey  
9:25 am The Life Cycle of a CLLB Cell Nicholas Chiorazzi, MD
9:40 am Break  
  Debate: Should interim FDG-PET be used to guide therapy in HL? Moderator: Andrew Zelenetz, MD, PhD
10:00 am Pro Craig Moskowitz, MD
10:15 am Con Nancy Bartlett, MD
10:30 am Management of HL in the Elderly Paul Hamlin, MD
10:45 am Comment Nancy Bartlett, MD
  Debate: Localized Relapse in HL: Optimal Strategies Moderator: Andrew Zelenetz, MD, PhD
10:50 am Transplant Craig Moskowitz, MD
11:05 am New Field, Dose and Techniques in Radiotherapy of Lymphomas Joachim Yahalom, MD
11:20 am Audience Question and Answer All Faculty
11:30 am Case-Based Discussion All Faculty
11:50 pm Post-Session Outcomes Survey  
12:00 pm Adjourn for Lunch  
12:00 - 1:15 pm Non- CME Lunch Symposium  or Lunch On Own  
New Directions in Hematologic Malignancies Moderator: Andrew Zelenetz, MD, PhD
1:15 pm Pre-session Outcomes Survey  
1:30 pm ADC's in Lymphoma Andrew Zelenetz, MD, PhD
1:45 pm Aurora Kinase Inhibition Johnathan Freidberg, MD
2:00 pm Kinase Inhibitors in Lymphoma Jennifer Brown, MD, PhD
2:15 pm Jak inihibtion in Lymhoma Anas Younes, MD
2:30 pm IMIDS in Lymphoma Andre Goy, MD
2:45 pm Audience Question and Answer All Faculty
2:55 pm Post-Session Outcomes Survey  
3:05 pm Closing Remarks Andrew Zelenetz, MD, PhD
3:15 pm Conference Adjourn  

Become a Member

Forgot Password?
Calendar of Events
Filter By